CEPI, Clover Biopharma advance COVID-19 vaccine development
BioSpectrum Asia|August 2020
We're offering this story for free to read so that you can stay updated on the COVID-19 outbreak
CEPI, Clover Biopharma advance COVID-19 vaccine development
CEPI, the Coalition for Epidemic Preparedness Innovations in Norway, has announced the expansion of its partnership with China-based Sichuan Clover Biopharmaceuticals, Inc. to rapidly advance the development and manufacture of Clover’s protein-based COVID-19 S-Trimer vaccine candidate, which is based on Clover’s proprietary Trimer-Tag vaccine technology platform.

articleRead

You can read up to 3 premium stories before you subscribe to Magzter GOLD

Log in, if you are already a subscriber

GoldLogo

Get unlimited access to thousands of curated premium stories, newspapers and 5,000+ magazines

READ THE ENTIRE ISSUE

August 2020